Abstract: Background. Patients with head and neck cancer often have multiple risk factors for coronary artery disease. Yet, little is known about the incidence of postoperative myocardial injury after major head and neck cancer surgery and its clinical relevance. The aim of this study was to determine the risk of postoperative myocardial injury in patients undergoing major head and neck cancer surgery.
Worldwide more than half a million new cases of head and neck cancer are diagnosed each year. 1 Head and neck cancer is commonly caused by long-term tobacco and alcohol abuse. 2 Long-term smoking and tobacco abuse increases the risk for not only cancer but also coronary artery disease and myocardial infarction. Most patients present with advanced-stage cancer, and many will undergo treatment with surgery either as the initial therapy or as salvage surgery after previously failed radiotherapy or chemoradiotherapy.
Surgery for head and neck cancer is complex and extensive because it commonly involves the resection of the tumor and unilateral or bilateral radical neck dissection and often requires transfer of a tissue flap for reconstruction. 1 Major head and neck cancer surgery frequently lasts more than 8 hours, involves large fluid shifts and blood loss, and causes significant postoperative inflammation and pain. All these factors are considered important risk factors for postoperative myocardial injury.
Postoperative myocardial injury is common and a major contributor to surgical morbidity and death. Up to 40% of all patients with coronary artery disease who undergo major noncardiac surgery have development of postoperative (silent) myocardial ischemia, and between 2% to 4% have myocardial infarction or heart-related death. [3] [4] [5] [6] Postoperative myocardial infarction is associated with a 27% to 40% mortality rate at 30 days after surgery.
after major head and neck cancer surgery has largely been overlooked. [8] [9] [10] Since 2003, Barnes-Jewish Hospital has implemented standardized, serial troponin measurements after all major head and neck cancer surgeries. Troponin is a myocardial protein and biomarker and, as such, the gold standard for diagnosing myocardial injury. As a consequence, we were able to study the incidence of postoperative myocardial injury in a large cohort of this patient population.
MATERIALS AND METHODS
Study Design and Population. In this retrospective cohort study, all consecutive patients were included who underwent major head and neck cancer surgery at Barnes-Jewish Hospital, St. Louis, MO, between April 2003 and July 2008 and had a postoperative troponin I (TnI) test measured (n ¼ 378). Major head and neck cancer surgery was defined as surgical procedures that included at least the resection of a primary tumor and neck dissection. Patients were excluded if the sentinel surgery was for diagnostic purposes only or did not include resection of a major area of tissue within the head and neck region (n ¼ 278 of 656). Consequently, these procedures were considered minor, and patients did not have a postoperative TnI test drawn. Patients were also excluded if the diagnosis was not head and neck cancer (erroneous listing). TNM staging information was not available, but we used the SEER staging criteria instead, which allow for a similar description of the disease extent.
Patients routinely had a preoperative cardiac evaluation performed by an anesthesiologist in the Preoperative Anesthesia Clinic. Only a minority of patients were seen additionally by a cardiologist and only at the surgeon's or anesthesiologist's request. There were no formal criteria for involvement of cardiologists in the preoperative assessment. All patients were entered in a head and neck cancer database of the Washington University Department of Otolaryngology. Individual patients' records were assessed from the Department of Otolaryngology medical records office or the Health Information Management Department at Barnes-Jewish Hospital either electronically or, in the case of older charts, by microfiched paper charts. Overall survival status was determined from a combination of the hospital-based tumor registry, the department-based head and neck cancer registry, or the Social Security Death Index. The final survival status was determined as of August 24, 2009 . Comorbidity refers to the other diseases, illnesses, or conditions that a patient with cancer has at the time of diagnosis and that may impact on treatment selection and outcome. 11 For this project, the overall severity of comorbidity at diagnosis was classified as none, mild, moderate, or severe with the Adult Comorbidity Evaluation 27 (ACE-27). 12 Assessment of Postoperative Myocardial Injury.
Myocardial injury was assessed by at least 3 serial TnI measurements: (1) immediately after surgery in the postanesthesia care unit, (2) 8 hours after surgery, and (3) 16 hours after surgery. Troponin I measurements could be canceled or additional ones ordered at the discretion of the clinical care team. Commonly, additional TnI tests were ordered when an elevated TnI was detected to determine the peak TnI concentration.
Myocardial injury was defined as an elevated, abnormal TnI test result at any postoperative time point. Cardiac TnI measurements were made by the Dimension RxL method (Dade Behring, now Siemens Healthcare, Malvern, PA), which was modified in 2003 to eliminate interference from HAMA antibodies, thereby improving low-end precision. 13 Initially, the clinical cut-off was a TnI concentration 0.1 ng/ mL, but during the last 3 years of the study period, the cut-off was lowered to 0.07 ng/mL because of the use of the more sensitive TnI assay. Myocardial infarction was defined according to the recently published universal definition of myocardial infarction 14 : elevated TnI plus electrocardiography changes consistent with myocardial ischemia or clinical symptoms of ischemia.
Statistical Analysis. Standard descriptive statistics were used to describe the distribution of main characteristics in patients with normal and elevated troponin levels. Mann-Whitney U and chi-square tests were used to investigate the presence of relationship between abnormal troponin and continuous and categorical level characteristics, respectively. The odds ratios (OR) produced by univariate logistic regression were used to identify the strength of such relationships and the influence of abnormal troponin in short-term and long-term survival. Significant predictors, identified from univariate logistic regression, were included in a multivariate logistic regression model. Kaplan-Meier survival analysis, as well as a Cox proportional hazards model, was used to compare the overall survival rates between patients with normal and abnormal troponin levels. The log-rank test was used to assess the statistical significance of the observed survival differences among groups. The statistical analysis was performed with the SPSS 17.0.2 software package (SPSS Inc., Chicago, IL). Two-tailed tests of significance were used, and significance was established at the p < .05 level. This study was approved by the Washington University School of Medicine Human Studies Committee and granted a waiver of informed consent.
RESULTS
A total of 378 patients who underwent major head and neck cancer surgery were included in the data analysis. The initial screen of the head and neck cancer patient database resulted in 656 patients, of whom 278 had to be excluded. Most excluded patients (87%) did not undergo major head and neck cancer surgery and consequently did not have a postoperative troponin test ordered.
Fifty-seven patients (15%) had development of an elevated abnormal TnI test result after surgery. Most patients with abnormal peak TnI levels (n ¼ 43, 75%) experienced a TnI elevation in the 0.07-0.2 ng/mL concentration range ( Figure 1A ). TnI levels peaked after a median of 10 hours after surgery (range, 0-72 hours), and 90% of all peak TnI levels occurred within the first 24 hours after surgery ( Figure 1B) . Of the 57 patients with an abnormal TnI test, 19 (33%) underwent a cardiology consultation, 10 (18%; 2.6% of total population) had concurrent electrocardiography changes consistent with an acute myocardial infarction, and 2 (3.5%) underwent emergent cardiac catheterization and percutaneous transluminal coronary angioplasty.
Predictors for Elevated Postoperative TnI. To identify predictors for elevated postoperative TnI, a univariate analysis was performed in which several variables were significantly associated with elevated postoperative TnI levels ( Table 1) . Preexisting renal insufficiency was associated with a nearly 5-fold higher risk for elevated postoperative TnI levels. Coronary artery disease, peripheral vascular disease and hypertension increased the risk between 2.2-and 2.8-fold. Patients who underwent previous combined chemotherapy and radiation had a 2.7-fold increased risk, whereas chemotherapy or radiation therapy alone did not increase the risk. Similar odds ratios of 2 were observed in patients with congestive heart failure and of higher age (>74 years), although these were not statistically significant. Neither smoking history, intraoperative blood loss, intraoperative hypotension, nor SEER tumor staging was a significant predictor. However, the use of tissue flaps for reconstruction was associated with a 1.7-fold increased risk of postoperative myocardial injury (OR 1.71, 95% CI: 0.96-3.04, p ¼ .07), which was marginally nonsignificant. Patients with tissue flaps had a higher blood loss (771 mL vs 442 mL, p < .0001). The duration of surgery and time under general anesthesia was similar between patients with an elevated and patients with a normal postoperative TnI test result.
In a multivariate logistic regression analysis, several predictors for postoperative TnI elevation identified earlier as significant predictors in the univariate analysis remained independently significant (Table 2) . These predictors were renal insufficiency, hypertension, and preceding combined chemotherapy and radiation. However, because of multicollinearity, several predictors (eg, peripheral vascular disease) had to be removed from the model to assure stability.
Elevated Postoperative TnI and Outcomes. In a next step, the relationship between elevated postoperative TnI and short-and long-term outcomes after head and neck cancer surgery was assessed. Patients with postoperative myocardial injury had a significantly longer length of stay in the hospital (median stay 8.5 vs 10.1 days; p ¼ .014) and intensive care unit (median stay: 3 vs 4.5 days; p ¼ .001). Postoperative myocardial injury was associated with a 6-fold increased risk of death at 30 days after surgery and an 8-fold increased risk of death at 60 days after surgery (Table 3) . Elevated TnI (adjusted OR 8.01; 95% CI 2.03 -31.56, p ¼ .003) and chemotherapy (adjusted OR 10.36; 95% 0.90 -118.89) were the strongest predictors of death at 60 days in a multivariate regression model (Table 4) .
At 1 year, patients with an abnormal postoperative TnI level were twice as likely to die (Figure 2 ; OR 1.93; 95% CI 1.02 -3.63; p ¼ .04). Long-term outcome over a 7-year period, with Kaplan-Meier survival analysis, was similar between patients with normal and elevated postoperative TnI levels. No difference in median survival was found between patients with an acute postoperative myocardial infarction versus TnI elevation (569 vs 652 days, p ¼ .90). 
DISCUSSION
The results of this study show that a substantial number of patients who undergo major head and neck cancer surgery experience postoperative myocardial injury. Furthermore, patients with development of postoperative troponin elevation had longer lengths of stays in the intensive care unit and hospital and were at considerably higher risk of death (6-to 8-fold) within the first 60 days after surgery. The increased mortality risk persisted for the whole first year after surgery. The results of this study also show that the cardiac risk after major head and neck cancer surgery was considerably underestimated from several smaller retrospective studies where the incidence of myocardial infarction after major head and neck cancer surgery was reported between 0.2% to 3.6%. 8, 10, [15] [16] [17] [18] [19] All these studies relied on retrospective identification of myocardial infarction diagnosed by clinical signs and electrocardiography. In the only study that included postoperative troponin tests, 16 of 65 (25%) patients had signs of myocardial injury. 9 It now seems likely that the incidence rate of postoperative myocardial injury after major head and neck cancer surgery approaches that after major vascular surgery. Largescale studies in major vascular surgery observed postoperative myocardial injury rates between 14% to 38%. [20] [21] [22] [23] [24] Patients with head and neck cancer share a similar risk profile with patients with peripheral vascular disease, predisposing them to atherosclerotic disease in addition to head and neck cancer. As with patients undergoing major vascular surgery, an abnormal TnI test result indicates a substantially increased short-term mortality risk. We observed an 8-fold increased risk for death at 60 days among patients with head and neck cancer, which is similar to a 6-fold increased mortality rate at 6 months after major vascular surgery. 25 Of particular clinical interest is the observation that even small TnI elevations, in the range of 0.1-0.2 ng/mL (''troponin leaks''), where most observed peak TnI values in our study were, are associated with important clinical events and outcomes. It is unlikely that small TnI elevations are directly causing adverse outcomes and increased mortality rates; rather they seem to indicate a very vulnerable patient population at high risk of subsequent myocardial infarction and death. Our study corroborates the importance of wellknown risk factors for postoperative myocardial injury, such as preexisting coronary artery disease, peripheral vascular disease, renal insufficiency, and hypertension. 3 Of note, however, is the fact that only 30% of patients, who had a postoperative TnI elevation, had a preoperative diagnosis of coronary artery disease. This indicates that coronary artery disease is likely underdiagnosed among patients with head and neck cancer and that clinicians should be suspicious about the presence of coronary artery disease in these patients. Unique among our study population was the increased cardiac risk associated with the use of flap procedures for reconstruction and previous treatment with both chemotherapy and radiation. Flap reconstructions typically last longer and are associated with more fluid shift, a substantially larger surgical area, and subsequently more surgical stress. Although not measured in this study, we believe these variables contribute to the higher incidence of postoperative myocardial injury.
Anticancer chemotherapy is known to be cardiotoxic, 26 and it appears that chemotherapy increases the postoperative cardiac risk after head and neck cancer surgery. The most frequent cytotoxic agents used to treat head and neck cancers are cisplatin and 5-fluorouracil, which have nephrotoxic and cardiotoxic effects, respectively. 27, 28 Additionally, combined use of chemotherapy and radiation is associated with higher treatment-related toxicities than use of radiation alone. 29, 30 Thus patients undergoing salvage surgery after previous treatment with both chemotherapy and radiation may be less resilient to the additional stresses related to subsequent major surgery.
This study had several strengths and limitations. The strengths include the fact that we were able to study a large cohort of consecutive major head and neck cancer surgeries performed over 6 years at a single academic center. Moreover, we were able to assess postoperative myocardial injury in a largely unbiased and complete fashion because serial TnI testing was routinely done after all major head and neck cancer surgeries. The availability of and reliance on TnI as the main outcome variable negated the need to use myocardial infarction diagnosed by clinical signs or electrocardiography only as primary outcome.
Limitations include our inability to assess preoperative TnI levels. Despite the theoretical possibility that some patients had abnormal TnI levels before surgery, several large-scale studies, including our own, show that this is uncommon. 31, 32 Despite having enrolled a large cohort of patients with head and neck cancer, several important preexisting conditions that were previously linked with postoperative myocardial injury, such as congestive heart failure, were too infrequent in our sample to be adequately statistically tested. Furthermore, a clear limitation of the study is that we were unable to assess the causes of death by having to rely on the Social Security Death Index. Although highly suggestive, the large increase in the short-term mortality rate could not be unequivocally attributed to cardiovascular causes. On the basis of the pattern of the 2 survival curves, it seems likely that within the first year after surgery, and particularly within 60 days, cardiovascular causes play a dominant role whereas cancer-related deaths increase thereafter. Other causes of death, however, are also plausible.
The clinical implications of this study are severalfold. First, patients who undergo major head and neck cancer surgery should be considered a vulnerable patient population at high risk for postoperative myocardial injury. Therefore close cardiac monitoring for myocardial injury, particularly within the first 24 hours after surgery, ideally by serial troponin measurements, seems prudent. Second, even small elevations of postoperative troponin should be considered a ''red flag,'' identifying a patient at significant risk of myocardial infarction and death within the first 60 days after surgery. On the basis of our data, we would recommend that most patients undergoing major head and neck cancer surgery should be followed up with serial postoperative troponin tests, particularly patients with cardiac risk factors. Moreover, patients with development of an elevated troponin level should be optimized regarding their cardiac care, for instance being started on aspirin, statins, or b-blockers in agreement with cardiology.
In conclusion, this study shows that patients who undergo major head and neck cancer surgery are at significant risk for postoperative myocardial injury. Patients with development of myocardial injury after head and neck cancer surgery have an 8-fold increased mortality rate within the first 60 days after surgery. On the basis of this evidence, patients should be closely monitored for myocardial injury after major head and neck cancer surgery, ideally with cardiac troponin levels measured during the first postoperative day. Primary and secondary prevention of myocardial infarction should be optimized for these patients.
